Recorded fact · drug.trial_access

drug.trial_access for deutetrabenazine

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact e3003116 resolves to.

The record

Fact id	`e3003116202f5a8d553a375c`
Entity	drug: deutetrabenazine
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "DEUTETRABENAZINE",
 "recruitingInterventionalCount": 2,
 "notYetRecruitingCount": 0,
 "byPhase": {
  "PHASE4": 2
 },
 "trials": [
  {
   "nctId": "NCT07105111",
   "briefTitle": "A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Neurocrine Biosciences",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-18",
   "startDate": "2025-08-29",
   "conditions": [
    "Schizophrenia",
    "Schizoaffective Disorder",
    "Bipolar Disorder"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07105111"
  },
  {
   "nctId": "NCT06997198",
   "briefTitle": "Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "University Hospitals Cleveland Medical Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-07-06",
   "startDate": "2026-06-22",
   "conditions": [
    "Tardive Dyskinesia",
    "Intellectual Disability",
    "Developmental Disabilities"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06997198"
  }
 ],
 "query": {
  "intr": "deutetrabenazine",
  "filterOverallStatus": "RECRUITING",
  "filterAdvanced": "AREA[StudyType]INTERVENTIONAL",
  "sort": "LastUpdatePostDate:desc",
  "apiVersion": "2.0.5"
 },
 "attribution": "ClinicalTrials.gov",
 "dataProcessedByRegistry": "2026-11-06T10:00:05",
 "modifications": "Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited."
}

SHA-256 of the exact stored value: 41bf2fc9da257d9ecb0a2a3de663d1883f5586225077c2fe9ccb83ad3040d4a4.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.